

## Instructions for Authors 2020

**General Policy.** ANTICANCER RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis, and therapy. Each article should include a concrete conclusion constituting of a “new piece of knowledge” backed up by scientific evidence. AR will also accept the following for publication: (a) Abstracts and Proceedings of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 120 words) and announcements of newly received books and journals related to cancer, and (d) Announcements of awards and prizes.

The principal aim of AR is to provide prompt publication (print and online) for original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works in the field of cancer research that are not under consideration for publication by another journal, and that they will not be published again in the same form. All authors should sign a submission letter confirming the approval of their article contents. All material submitted to AR will be subject to peer-review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. All manuscripts submitted to AR are urgently treated with absolute confidence, with access restricted to the Managing Editor, the journal’s secretary, the reviewers and the printers. The Editors reserve the right to improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

**NIH Open Access Policy.** The journal acknowledges that authors of NIH-funded research retain the right to provide a copy of the published manuscript to the NIH four months after publication in ANTICANCER RESEARCH, for public archiving in PubMed Central.

**Copyright.** Once a manuscript has been published in ANTICANCER RESEARCH, which is a copyrighted publication, the legal ownership of all published parts of the paper has been transferred from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without the written consent of the Managing Editor or Publisher.

**Format.** Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the “Shorter Oxford English Dictionary”.

**Manuscripts.** Submitted manuscripts exceeding 4 printed pages will be subject to excess page charges. The 4 printed pages correspond approximately to twelve (12) document pages (~250 words per double-spaced typed page in Arial 12), including abstract, text, tables, figures, and references. All manuscripts should be divided into the following sections: (a) *First page* including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication “review”, “clinical”, “epidemiological”, or “experimental” study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) *Abstract* not exceeding 150 words, organized according to the following headings: Background/Aim – Materials and Methods/Patients and Methods – Results – Conclusion; (c) *Introduction*; (d) *Materials and Methods/Patients and Methods*; (e) *Results*; (f) *Discussion*; (g) *Conflicts of Interest*; (h) *Authors’ contributions*; (i) *Acknowledgements*; (j) *References*. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author’s opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

**Figures.** All figures should appear at the end of the submitted document file. Once a manuscript is accepted all figures and graphs should be submitted separately in either jpg, tiff or pdf format and at a minimum resolution of 300 dpi. Graphs must be submitted as pictures made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated. Pages that include color figures are subject to color charges..

**Tables.** All tables should appear at the end of the submitted document file. Once a manuscript is accepted, each table should be submitted separately, typed double-spaced. Tables should be numbered with Roman numerals and should include a short title.

**References.** Authors must assume responsibility for the accuracy of the references used. Citations for the reference sections of submitted works should follow the form below and must be numbered consecutively. In the text, references should be cited by number in parenthesis. Examples: 1 Kenyon J, Liu W and Dalglish A: Report of objective clinical responses of cancer patients to pharmaceutical-grade synthetic cannabidiol. *Anticancer Res* 38(10): 5831-5835, 2018. PMID: 30275207. DOI: 10.21873/anticancer.12924. (PMIDs and DOIs only if applicable). 2 McGuire WL and Chamnes GC: Studies on the oestrogen receptor in breast cancer. In: *Receptors for Reproductive Hormones*. O’Malley BW, Chamnes GC (eds.). New York, Plenum Publ Corp., pp 113-136, 1973. 3 Global Health Estimates 2015: Disease Burden by Cause, Age, Sex, by Country and by Region,

2000-2015. Geneva, World Health Organisation, 2016. Available at [http://www.who.int/healthinfo/global\\_burden\\_disease/estimates/en/index2.html](http://www.who.int/healthinfo/global_burden_disease/estimates/en/index2.html). Last accessed on 3rd April 2018. (The web address should link directly to the cited information and not to a generic webpage).

**Nomenclature and Abbreviations.** Nomenclature should follow that given in “Chemical Abstracts”, “Index Medicus”, “Merck Index”, “IUPAC -IUB”, “Bergey’s Manual of Determinative Bacteriology”, The CBE Manual for Authors, Editors and Publishers (6th edition, 1994), and MIAME Standard for Microarray Data. Human gene symbols may be obtained from the HUGO Gene Nomenclature Committee (HGNC) (<http://www.gene.ucl.ac.uk/>). Approved mouse nomenclature may be obtained from <http://www.informatics.jax.org/>. Standard abbreviations are preferable. If a new abbreviation is used, it must be defined on first usage.

**Clinical Trials.** Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text.

For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by “ISRCTN”). Please note that there is no space between the prefix “ISRCTN” and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by ‘NCT’). Please note that there is no space between the prefix ‘NCT’ and the number. Example: NCT00001789.

**Ethical Policies and Standards.** ANTICANCER RESEARCH agrees with and follows the “Uniform Requirements for Manuscripts Submitted to Biomedical Journals” established by the International Committee of Medical Journal Editors in 1978 and updated in October 2001 ([www.icmje.org](http://www.icmje.org)). Microarray data analysis should comply with the “Minimum Information About Microarray Experiments (MIAME) standard”. Specific guidelines are provided at the “Microarray Gene Expression Data Society” (MGED) website. Presentation of genome sequences should follow the guidelines of the NHGRI Policy on Release of Human Genomic Sequence Data. Research involving human beings must adhere to the principles of the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects, effective December 13, 2001. Research involving animals must adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society. The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Research involving the use of human fetuses, foetal tissue, embryos and embryonic cells should adhere to the U.S. Public Law 103-41, effective December 13, 2001.

**Submission of Manuscripts.** Please follow the Instructions for Authors regarding the format of your manuscript and references. Manuscripts must be submitted only through our online submission system at: <http://www.iiar-submissions.com/login.html> In case a submission is incomplete, the corresponding Author will be notified accordingly. Questions regarding difficulties in using the online submission system should be addressed to: email: [journals@iiar-anticancer.org](mailto:journals@iiar-anticancer.org)


**Galley Proofs.** Unless otherwise indicated, galley proofs will be sent to the corresponding Author of the submission. Corrections of galley proofs should be limited to typographical errors. Reprints, PDF files, and/or Open Access may be ordered after the acceptance of the paper. Authors of online open access articles are entitled to a complimentary online subscription to Anticancer Research for the current year and all previous digital content since 2004 (upon request to the Subscriptions Office). Galley proofs should be returned corrected to the Editorial Office by email ([iiar@iiar-anticancer.org](mailto:iiar@iiar-anticancer.org)) within two days.

### **Specific information and additional instructions for Authors**

1. Anticancer Research (AR) closely follows the new developments in all fields of experimental and clinical cancer research by (a) inviting reviews on topics of immediate importance and substantial progress in the last three years, and (b) providing the highest priority for rapid publication to manuscripts presenting original results judged to be of exceptional value. Theoretical papers will only be considered and accepted if they bear a significant impact or formulate existing knowledge for the benefit of research progress.
2. Anticancer Research will consider the publication of conference proceedings and/or abstracts provided that the material submitted fulfils the quality requirements and instructions of the journal, following the regular review process by two suitable referees.
3. An acknowledgement of receipt, including the article number, title and date of receipt is sent to the corresponding author of each manuscript upon receipt. If this receipt is not received within 20 days from submission, the author should call or write to the Editorial Office to ensure that the manuscript (or the receipt) was not lost in the mail or during electronic submission.
4. Each manuscript submitted to AR is sent for peer-review in confidence to two-three suitable referees with the request to return the manuscript with their comments to the Editorial Office within 12 days from receipt. If reviewers need a longer time or wish to send the manuscript to another expert, the manuscript may be returned to the Editorial Office with a delay. All manuscripts submitted to AR, are treated in confidence, without access to any person other than the Managing Editor, the journal’s secretary, the reviewers and the printers.

5. All accepted manuscripts are carefully corrected in style and language, if necessary, to make presentation clear. (There is no fee for this service). Every effort is made (a) to maintain the personal style of the author's writing and (b) to avoid change of meaning. Authors will be requested to examine carefully manuscripts which have undergone language correction at the pre-proof or proof stage.
  6. Authors should pay attention to the following points when writing an article for AR:
    - The Instructions to Authors must be followed in every detail.
    - The presentation of the experimental methods should be clear and complete in every detail facilitating reproducibility by other scientists.
    - The presentation of results should be simple and straightforward in style. Results and discussion should not be combined into one section, unless the paper is short.
    - Results given in figures should not be repeated in tables.
    - Figures (graphs or photographs) should be prepared at a width of 8 or 17 cm with legible numbers and lettering.
    - Photographs should be clear with high contrast, presenting the actual observation described in the legend and in the text. Each legend should provide a complete description, being self-explanatory, including technique of preparation, information about the specimen and magnification.
    - Statistical analysis should be elaborated wherever it is necessary. Simplification of presentation by giving only numerical or % values should be avoided.
    - Fidelity of the techniques and reproducibility of the results, should be points of particular importance in the discussion section. Authors are advised to check the correctness of their methods and results carefully before writing an article. Probable or dubious explanations should be avoided.
    - Authors should not cite results submitted for publication in the reference section. Such results may be described briefly in the text with a note in parenthesis (submitted for publication by... authors, year).
    - References. Each article should address, list and discuss the entire spectrum of current publications relevant to its field.
    - By following these instructions, Authors will facilitate a more rapid review and processing of their manuscripts and will provide the readers with concise and useful papers.
  7. Following review and acceptance, a manuscript is examined in language and style, and galley proofs are rapidly prepared. Second proofs are not sent unless required.
  8. Authors should correct their galley proofs very carefully and preferably twice. An additional correction by a colleague always proves to be useful. Particular attention should be paid to chemical formulas, mathematical equations, symbols, medical nomenclature etc. Any system of correction marks can be used in a clear manner, preferably with a red pen. Additions or clarifications are allowed provided that they improve the presentation but do not bring new results (no fee).
  9. Articles submitted to AR may be rejected without review if:
    - they do not fall within the journal's policy.
    - they do not follow the instructions for authors.
    - language is unclear.
    - results are not sufficient to support a final conclusion.
    - results are not objectively based on valid experiments.
    - they repeat results already published by the same or other authors before the submission to AR.
    - plagiarism is detected by plagiarism screening services.(Rejection rate (2016): 66%).
  10. Authors who wish to prepare a review should contact the Managing Editor of the journal in order to get confirmation of interest in the particular topic of the review. The expression of interest by the Managing Editor does not necessarily imply acceptance of the review by the journal.
  11. Authors may inquire information about the status of their manuscript(s) by calling the Editorial Office at +30-22950-53389, Monday to Friday 9.00-16.00 (Athens time), or by sending an e-mail to [journals@iiar-anticancer.org](mailto:journals@iiar-anticancer.org)
  12. Authors who wish to edit a special issue on a particular topic should contact the Managing Editor.
  13. Authors, Editors and Publishers of books are welcome to submit their books for immediate review in AR. There is no fee for this service.
- (This text is a combination of advice and suggestions contributed by Editors, Authors, Readers and the Managing Editor of AR).

**Copyright© 2020** - International Institute of Anticancer Research (G.J. Delinasios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.



## General Policy

- **CANCER GENOMICS & PROTEOMICS (CGP)** welcomes submissions of original high quality articles and reviews on all aspects of the application of genomic and proteomic technologies to experimental and clinical cancer research. The journal's scientific spectrum includes: (a) molecular causes of carcinogenesis, cancer progression and metastasis; (b) structural and functional aspects of genes in the cancer cell; (c) advances in genomic and proteomic technologies applicable to cancer research; (d) anticancer drug design and drug development. A main aim of CGP is to ensure the prompt and confidential review, and rapid publication of original works and reviews, generally within 1-3 months from submission.
- CGP is published bimonthly by the **International Institute of Anticancer Research (IIAR)** and is available online only and open access with **Stanford University HighWire Press**. For more information please visit our website [www.cgip.iiarjournals.org](http://www.cgip.iiarjournals.org).
- **Editorial Office:** International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Rd., P.O. Box 22, Kapandriti, Attiki 19014, Greece. Tel: +30 22950 52945, Fax: +30 22950 53389.
- **U.S. Branch:** Anticancer Research Inc., USA, 111 Bay Avenue, Highlands, NJ, USA.
- **E-mail:** [journals@iiar-anticancer.org](mailto:journals@iiar-anticancer.org); IIAR WEBSITES: [www.iiar-anticancer.org](http://www.iiar-anticancer.org) and [www.iiarjournals.org](http://www.iiarjournals.org)

## ● Selection of Recent Articles

Duplex DNA from Sites of Helicase-Polymerase Uncoupling Links Non-B DNA Structure Formation to Replicative Stress. C. AMPARO, J. CLARK, V. BEDELL, J.L. MURATA-COLLINS, M. MARTELLA, F. PICHIORRI, E.F. WARNER, M. ABDELHAMID, Z.A.E. WALLER, S.S. SMITH (Duarte, CA, USA; Norwich, UK)

Pazopanib Inhibits Tumor Growth, Lymph-node Metastasis and Lymphangiogenesis of an Orthotopic Mouse of Colorectal Cancer. G. ZHU, M. ZHAO, Q. HAN, Y. TAN, Y. SUN, M. BOUVET, S.R. SINGH, J. YE, R.M. HOFFMAN (San Diego, CA; Frederick, MD, USA; Fuzhou, PR China)

KIF15 Expression in Tumor-associated Monocytes Is a Prognostic Biomarker in Hepatocellular Carcinoma. A. KITAGAWA, T. MASUDA, J. TAKAHASHI, T. TOBO, M. NODA, Y. KURODA, Q. HU, Y. KOUYAMA, Y. KOBAYASHI, S. KURAMITSU, K. SATO, A. FUJII, Y. YOSHIKAWA, H. WAKIYAMA, D. SHIMIZU, Y. TSURUDA, H. EGUCHI, Y. DOKI, M. MORI, K. MIMORI (Oita; Osaka; Fukuoka, Japan)

Chromosome Translocation t(14;21)(q11;q22) Activates Both OLIG1 and OLIG2 in Pediatric T-cell Lymphoblastic Malignancies and May Signify Adverse Prognosis. I. PANAGOPOULOS, L. GORUNOVA, I.M. RINVOLL JOHANNSDOTTIR, K. ANDERSEN, A. HOLTH, K. BEISKE, S. HEIM (Oslo, Norway)

Whole Transcriptomic Analysis of Apigenin-mediated Influence on TNF $\alpha$  Immuno-activated MDA-MB-231 Breast Cancer Cells. D. BAUER, E. MAZZIO, K.F.A. SOLIMAN (Tallahassee, FL, USA)

Significant Association Between the MiR146a Genotypes and Susceptibility to Childhood Acute Lymphoblastic Leukemia in Taiwan. J.-S. PEI, W.-S. CHANG, P.-C. HSU, C.-C. CHEN, Y.-T. CHIN, T.-L. HUANG, Y.-N. HSU, C.-C. KUO, Y.-C. WANG, C.-W. TSAI, C.-L. GONG, D.-T. BAU (Taoyuan; Taichung, Taiwan, ROC)

Clonal Relationship Between Lichen Sclerosus, Differentiated Vulvar Intraepithelial Neoplasia and Non HPV-related Vulvar Squamous Cell Carcinoma. A.-F.W. POUWER, L.C.G. VAN DEN EINDEN, M. VAN DER LINDEN, J.Y. HEHIR-KWA, J. YU, K.M. HENDRIKS, E.J. KAMPING, A. EIJKELBOOM, L.F.A.G. MASSUGER, J. BULTEN, A.A.G. VAN TILBORG, J.A. DE HULLU, R.P. KUIPER (Nijmegen; Utrecht, the Netherlands)

Identification of Novel Prognosis and Prediction Markers in Advanced Prostate Cancer Tissues Based on Quantitative Proteomics. O.K. KWON, Y.-S. HA, A.Y. NA, S.Y. CHUN, T.G. KWON, J.N. LEE, S. LEE (Daegu, Republic of Korea)

BRD4-Regulated Molecular Targets in Mantle Cell Lymphoma: Insights into Targeted Therapeutic Approach. T. TSUKAMOTO, S. NAKAHATA, R. SATO, A. KANAI, M. NAKANO, Y. CHINEN, S. MAEGAWA-MATSUI, Y. MATSUMURA-KIMOTO, T. TAKIMOTO-SHIMOMURA, Y. MIZUNO, S. KUWAHARA-OTA, Y. KAWAJI, M. TANIWAKI, T. INABA, K. TASHIRO, K. MORISHITA, J. KURODA (Kyoto; Miyazaki; Hiroshima, Japan)

MicroRNAs Involved in Metastasis of Hepatocellular Carcinoma: Target Candidates, Functionality and Efficacy in Animal Models and Prognostic Relevance. U.H. WEIDLE, D. SCHMID, F. BIRZELE, U. BRINKMANN (Penzberg, Germany; Basel, Switzerland)

Increased Expression of Gremlin1 Promotes Proliferation and Epithelial Mesenchymal Transition in Gastric Cancer Cells and Correlates With Poor Prognosis of Patients With Gastric Cancer. Z. SUN, S. CAI, C. LIU, Y. CUI, J. JI, W.G. JIANG, L. YE (Cardiff, UK; Beijing, PR China)

**Contents***Reviews*

Reasons to Reconsider Risk Associated With Power Morcellation of Uterine Fibroids. C. HOLZMANN, W. KUEPKER, B. ROMMEL, B. HELMKE, J. BULLERDIEK (Rostock; Baden Baden-Buehl; Bremen; Stade, Germany) ..... 1

Three-dimensional Versus Two-dimensional Laparoscopic Surgery for Colorectal Cancer: Systematic Review and Meta-analysis. G. PANTALOS, D. PATSOURAS, E. SPARTALIS, D. DIMITROULIS, G. TSOUROULIS, N. NIKITEAS (Athens, Greece) ..... 11

Intraoperative Indocyanine Green (ICG) Angiography for the Identification of the Parathyroid Glands: Current Evidence and Future Perspectives. E. SPARTALIS, G. NTOKOS, K. GEORGIOU, G. ZOGRAFOS, G. TSOUROULIS, D. DIMITROULIS, N. NIKITEAS (Athens, Greece) ..... 23

*Experimental Studies*

Fanconi Anemia Mouse Genotype-specific Mitigation of Total Body Irradiation by GS-Nitroxide JP4-039. M.W. EPPERLY, R. FISHER, X. ZHANG, W. HOU, D. SHIELDS, P. WIPF, H. WANG, S. THERMOZIER, J.S. GREENBERGER (Pittsburgh, PA, USA) ..... 33

Second-generation Probiotics Producing IL-22 Increase Survival of Mice After Total Body Irradiation. X. ZHANG, R. FISHER, W. HOU, D. SHIELDS, M.W. EPPERLY, H. WANG, L. WEI, B.J. LEIBOWITZ, J. YU, L.M. ALEXANDER, J.-P. VAN PUKEREN, S. WATKINS, P. WIPF, J.S. GREENBERGER (Pittsburgh, PA; Madison, WI, USA) ..... 39

The Association of MMP7 Genotype With Pterygium. P.-S. HU, Y.-C. WANG, C.-H. LIAO, N.-Y. HSIA, M.-F. WU, J.-S. YANG, C.-C. YU, W.-S. CHANG, D.-T. BAU, C.-W. TSAI (Taichung; Changhua; Taipei, Taiwan, ROC) ..... 51

*Contents continued on the back cover*

**ISSN (online): 1791-7549**

**General Policy**

- **IN VIVO** is a multidisciplinary journal designed to bring together original high quality works and reviews on experimental and clinical biomedical research within the frames of human physiology, pathology and disease management. A special focus of the journal is the publication of works on: (a) Experimental development and application of new diagnostic procedures; (b) Pharmacological and toxicological evaluation of new drugs and drug combinations; (c) Clinical trials; (d) Development and characterization of models of biomedical research.
- The principal aim of **IN VIVO** is to provide prompt online publication for accepted articles, generally within 1-2 months from final acceptance (3 months from submission).
- **Editorial Office:** International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Rd., P.O. Box 22, Kapandriti, Attiki 19014, Greece. Tel: +30 22950 52945, Fax: +30 22950 53389.

**U.S. Branch:** Anticancer Research Inc., USA, 111 Bay Avenue, Highlands, NJ, USA.

- **E-mail:** journals@iiar-anticancer.org; IIAR WEBSITES: www.iiar-anticancer.org and www.iiarjournals.org

- **International Journal of Experimental and Clinical Pathophysiology and Drug Research**
- **Published bimonthly by the International Institute of Anticancer Research**
- **Available online only and open access with Stanford University HighWire Press**

**Selection of Recent Articles**

Fanconi Anemia Mouse Genotype-specific Mitigation of Total Body Irradiation by GS-Nitroxide JP4-039. M.W. EPPERLY, R. FISHER, X. ZHANG, W. HOU, D. SHIELDS, P. WIPF, H. WANG, S. THERMOZIER, J.S. GREENBERGER (Pittsburgh, PA, USA)

Oral Recombinant Methioninase Prevents Obesity in Mice on a High Fat Diet. Y. TASHIRO, Q. HAN, Y. TAN, N. SUGISAWA, J. YAMAMOTO, H. NISHINO, S. INUBUSHI, T. HIGUCHI, T. AOKI, M. MURAKAMI, R.M. HOFFMAN (San Diego, CA, USA; Tokyo, Japan)

Radical-scavenging and Pro-/anti-inflammatory Activity of Tetracycline and Related Phenolic Compounds With or Without Visible Light Irradiation. Y. MURAKAMI, A. KAWATA, S. SUZUKI, S. FUJISAWA (Sakado, Japan)

TRPV1 Mediates Glucose-induced Insulin Secretion Through Releasing Neuropeptides. B. ZHONG, S. MA, D.H. WANG (East Lansing, MI, USA)

Health-related Quality of Life of Breast Cancer Survivors Attending an Exercise Intervention Study: A Five-year Follow-up. E. ROINE, H. SINTONEN, P.-L. KELLOKUMPU-LEHTINEN, H. PENTTINEN, M. UTRAIINEN, L. VEHMANEN, R. HUOVINEN, H. KAUTIAINEN, R. NIKANDER, C. BLOMQUIST, T. SAARTO (Helsinki; Tampere; Turku; Kuopio; Jyväskylä, Finland)

The Anthropometric Assessment With the Bioimpedance Method Is Associated With the Prognosis of Cirrhotic Patients. E.-I. MORIWAKI, H. ENOMOTO, M. SAITO, N. HARA, H. NISHIKAWA, T. NISHIMURA, Y. IWATA, H. IJIMA, S. NISHIGUCHI (Hyogo; Osaka, Japan)

Surgical Intervention for Uterine Fibroids. Our 4-Year Experience and Literature Review: Is It Time to Centralise Care Provision Via Specialist Fibroid Centres? S.M. STRONG, M. SIDERIS, Z. MAGAMA, S. ROUABHI, F. ODEJINMI (London, UK)

Symptom Burden in Patients With Reduced Performance Status at the Start of Palliative Radiotherapy. C. NIEDER, T.A. KÄMPPE (Bodø; Tromsø, Norway)

The Association of MMP7 Genotype With Pterygium. P.-S. HU, Y.-C. WANG, C.-H. LIAO, N.-Y. HSIA, M.-F. WU, J.-S. YANG, C.-C. YU, W.-S. CHANG, D.-T. BAU, C.-W. TSAI (Taichung; Changhua; Taipei, Taiwan, ROC)

Reasons to Reconsider Risk Associated With Power Morcellation of Uterine Fibroids. C. HOLZMANN, W. KUEPKER, B. ROMMEL, B. HELMKE, J. BULLERDIEK (Rostock; Buehl; Bremen; Stade, Germany)

Chemoprevention of Breast Cancer With Vitamins and Micronutrients: A Concise Review. KEFAH MOKBEL, KINAN MOKBEL (London, UK)

Serum Level of microRNA-375-3p Is not a Reliable Biomarker of Teratoma? G. BELGE, F. GROBELNY, C. MATTHIES, A. RADTKE, K.-P. DIECKMANN (Bremen; Hamburg, Germany)

Targeting BCL-2 as a Therapeutic Strategy for Primary p210BCR-ABL1-positive B-ALL Cells. M. MASSIMINO, E. TIRRO, S. STELLA, M.S. PENNISI, S.R. VITALE, A. PUMA, C. ROMANO, S. DI GREGORIO, M.A. ROMEO, F. DI RAIMONDO, L. MANZELLA (Catania, Italy)

Factors Raising Serum Ammonia Level During Lenvatinib Treatment of Patients With Hepatocellular Carcinoma. R. NARITA, K. KOTOH, A. YONEDA, M. MOTOMURA, M. HARADA ( <i>Oita; Kitakyushu; Fukuoka, Japan</i> ) .....	5271
Salvage Chemotherapy After Nivolumab for Recurrent or Metastatic Head and Neck Carcinoma. C. FUSHIMI, I. OKAMOTO, T. MATSUKI, T. MASUBUCHI, T. OKADA, H. SATO, K. TSUKAHARA, T. KONDO, T. YAMASHITA, K. HANYU, G. OMURA, H. TAKAHASHI, Y. TADA, K. MIURA ( <i>Tokyo; Sagami-hara; Hachioji; Yokohama, Japan</i> ) .....	5277
Continuous Administration of Bevacizumab After Disease Progression in Recurrent Ovarian Cancer: A Retrospective Observational Study. T. TANIGAWA, M. MATODA, M. OMI, Y. AOKI, S. NETSU, H. NOMURA, S. OKAMOTO, K. OMATSU, M. YUNOKAWA, H. KANAO, N. TAKESHIMA ( <i>Tokyo, Japan</i> ) .....	5285
Severe Gastrointestinal Mucositis Following Concurrent Palbociclib and Palliative Radiation Therapy. U.M. NASIR, A.M. MOZEIKA, M. SAYAN, I. JAN, N. KOWAL, B. HAFFTY, S. AHLAWAT, N. KOTHARI ( <i>Newark; New Brunswick, NJ, USA</i> ) .....	5291
Randomized Study of Postoperative Single Intravesical Instillation With Pirarubicin and Mitomycin C for Low-risk Bladder Cancer. S. YAMAMOTO, Y. KAGEYAMA, Y. FUJII, T. AIZAWA, S. URAKAMI, I. FUKUI ( <i>Tokyo; Saitama, Japan</i> ) .....	5295
Phase I Study of the Administration of Low-dose Perioperative Human Atrial Natriuretic Peptide in Patients With Resectable Colorectal Cancer. H. TAKAHASHI, T. TAKEDA, Y. NISHIZAWA, T. OGINO, N. MIYOSHI, C. MATSUDA, H. YAMAMOTO, T. MIZUSHIMA, Y. DOKI, H. EGUCHI ( <i>Osaka, Japan</i> ) .....	5301
Recovery of the Sensitivity to Anti-PD-1 Antibody by Celecoxib in Lung Cancer. K. KOBAYASHI, K. KAIRA, H. KAGAMU ( <i>Saitama, Japan</i> ) .....	5309
Second-line Dasatinib Therapy Improved Compliance and Deep Molecular Responses in Imatinib-intolerant Chronic Myeloid Leukemia Patients. U. MARKOVIC, A. BULLA, S. LEOTTA, S. STELLA, M.L. CONSOLI, L. TAMBÈ, C. CONTICELLO, F. DI RAIMONDO, F. STAGNO ( <i>Catania, Italy</i> ) .....	5313
Clinical Outcome of Surgically Treated Leiomyosarcoma of the Extremities: A Retrospective Overview. A. VAN BEECK, M. VAN DE SANDE, V. VAN PRAAG, D. DAMMERER, J. MICHELSSEN, T. SCHUBERT, B. KAPANCI, F. SHUMELINSKY, J. SOMVILLE, S. DIJKSTRA ( <i>Antwerp; Brussels, Belgium; Leiden, the Netherlands; Innsbruck, Austria</i> ) .....	5319
Erratum .....	5327

Temozolomide and AZD7762 Induce Synergistic Cytotoxicity Effects on Human Glioma Cells. Y. CHEN, B.-J. TSENG, Y.-H. TSAI, S.-H. TSENG ( <i>New Taipei; Taoyuan; Taipei, Taiwan, ROC</i> ).....	5141
Static Magnetic Stimulation Induces Cell-type Specific Alterations in the Viability of SH-SY5Y Neuroblastoma Cell Line. H.R. MEDEIROS, J.A.F. ASSUMPCAO, L.F. MEDEIROS, M. STAPENHORST, L. NUNES, N.A.C. HENCKES, C. URIBE CRUZ, F. FREGNI, P.R.S. SANCHES, F.S.O. OLIVEIRA, W. CAUMO, E.O. CIRNE-LIMA, I.L.S. TORRES ( <i>Porto Alegre, RS, Brazil; Boston, MA, USA</i> ) .....	5151
Redox-related Molecular Mechanism of Sensitizing Colon Cancer Cells to Camptothecin Analog SN38. B. NIKOLOVA, S. SEMKOVA, I. TSONEVA, E. STOYANOVA, P. LEFTEROV, D. LAZAROVA, Z. ZHELEV, I. AOKI, T. HIGASHI, R. BAKALOVA ( <i>Sofia, Stara Zagora, Bulgaria; Chiba, Japan</i> ).....	5159
Inhibitory Effects of Beraprost Sodium in Murine Hepatic Sinusoidal Obstruction Syndrome. M. NAKURA, T. MIYASHITA, Y. YAMAMOTO, S. TAKADA, S. KANO, H. TAJIMA, H. TAKAMURA, T. OHTA ( <i>Kanazawa; Kahoku, Japan</i> ) .....	5171
Advanced Non-linear Mathematical Model for the Prediction of the Activity of a Putative Anticancer Agent in Human-to-mouse Cancer Xenografts. S.G. LILIOPOULOS, G.S. STAVRAKAKIS, K.S. DIMAS ( <i>Chania; Larissa, Greece</i> ) .....	5181
Methylsulfonylmethane Induces Cell Cycle Arrest and Apoptosis, and Suppresses the Stemness Potential of HT-29 Cells. D.H. KIM, D.Y. KANG, N. SP, E.S. JO, A. RUGAMBA, K.-J. JANG, Y.M. YANG ( <i>Chungju, Republic of Korea</i> ) .....	5191
Total Flavonoids Isolated from <i>Diospyros kaki</i> L. f. Leaves Induced Apoptosis and Oxidative Stress in Human Cancer Cells. L. CHEN, Y. GUO, G. ALSAIF, Y. GAO ( <i>Murfreesboro, TN, USA; Liuzhou; Nanning, PR China</i> )...	5201
Anti-tumor Activity of the Small Molecule Inhibitor PRI-724 Against $\beta$ -Catenin-activated Hepatocellular Carcinoma. R. GABATA, K. HARADA, Y. MIZUTANI, H. OUCHI, K. YOSHIMURA, Y. SATO, A. KITAO, K. KIMURA, H. KOUJI, T. MIYASHITA, H. TAJIMA, T. OHTA ( <i>Kanazawa; Tokyo; Oita; Fujisawa, Japan</i> ) .....	5211
Gamma/Delta T-Cells Enhance Carboplatin-induced Cytotoxicity Towards Advanced Bladder Cancer Cells. Y. PAN, Y.-H. CHIU, S.-C. CHIU, D.-Y. CHO, L.-M. LEE, Y.-C. WEN, J. WHANG-PENG, C.-H. HSIAO, P.-H. SHIH ( <i>Taipei; Taichung, Taiwan, ROC</i> ).....	5221
<i>Clinical Studies</i>	
Phase I Study of LFA102 in Patients With Advanced Breast Cancer or Castration-resistant Prostate Cancer. H. MINAMI, Y. ANDO, K. TAMURA, T. TAJIMA, R. ISAACS ( <i>Kobe; Nagoya; Tokyo, Japan; East Hanover, NJ, USA</i> ) .....	5229
Mogamulizumab Plus EPOCH Therapy for Patients With Newly Diagnosed Aggressive Adult T-cell Leukemia/lymphoma. T. JO, K. MATSUZAKA, H. SHIOYA, H. TOMINAGA, T. SAKAI, Y. KANEKO, S. HAYASHI, M. MATSUO, J. TAGUCHI, K. ABE, K. SHIGEMATSU, R. KUBOTA-KOKETSU ( <i>Nagasaki; Osaka, Japan</i> ) .....	5237
Higher BMI, But Not Sarcopenia, Is Associated With Pembrolizumab-related Toxicity in Patients With Advanced Melanoma. J.B. HU, S. RAVICHANDRAN, C. RUSHING, G.M. BEASLEY, B.A. HANKS, S.-H. JUNG, A.K.S. SALAMA, L. HO, P.J. MOSCA ( <i>Durham, NC, USA</i> ) .....	5245
Cabazitaxel - A Treatment Option in Recurrent Platinum-resistant Ovarian Cancer. C. VESTERGAARD MADSEN, P. ADIMI, A. JAKOBSEN, K.D. STEFFENSEN ( <i>Vejle; Odense, Denmark</i> ) .....	5255
Successful Management of Platinum-resistant Ovarian Cancer by Weekly Nedaplatin Followed by Olaparib: Three Case Reports. S. SOEDA, T. WATANABE, N. KAMO, T. SATO, C. OKABE, M. UEDA, Y. ENDO, K. MANABU, S. NOMURA, S. FURUKAWA, H. NISHIGORI, T. TAKAHASHI, K. FUJIMORI ( <i>Fukushima, Japan</i> ) .....	5263

The Effects of Newly Synthesized Platinum(IV) Complexes on Cytotoxicity and Radiosensitization of Human Tumour Cells <i>In Vitro</i> . M. PETROVIC, S. POPOVIC, D. BASKIC, M. TODOROVIC, P. DJURDJEVIC, A. RISTIC-FIRA, O. KETA, V. PETKOVIC, L. KORICANAC, D. STOJKOVIC, V. JEVTIC, S. TRIFUNOVIC, D. TODOROVIC ( <i>Kragujevac; Belgrade, Serbia</i> ) .....	5001
Assessment of <i>In Vitro</i> Anti-melanoma Potential of <i>Ephedranthus pisocarpus</i> R.E.Fr. L.K. BESERRA SANTOS, M.D. ALVES VERAS, K.K. GADELHA MARQUES, M.M. DE MORAES ALVES, A. NOGUEIRA MENDES, F.A. DE AMORIM CARVALHO, M. VIEIRA SOBRAL, M.H. CHAVES, J.C. RAMOS GONÇALVES ( <i>Teresina; João Pessoa, Brazil</i> ) .....	5015
A New Ciprofloxacin-derivative Inhibits Proliferation and Suppresses the Migration Ability of HeLa Cells. M. FATHY, S. SUN, Q.-L. ZHAO, M. ABDEL-AZIZ, G.E.-D.A. ABUO-RAHMA, S. AWALE, T. NIKAIDO ( <i>Toyama, Japan; Minia, Egypt</i> ) .....	5025
Up-regulation of Death Receptor 5/TRAIL-R2 Mediates Apoptosis Induced by <i>N,N'</i> -[(3,4-dimethoxyphenyl)methylene] Biscinnamide in Cancer Cells. H. II, S. NAKATA, J. UENISHI ( <i>Kyoto; Osaka, Japan</i> ).....	5035
Inhibitory Effect of Eicosapentaenoic Acid on the Migration of the Esophageal Squamous Cell Carcinoma Cell Line TE-1. H. KUBOTA, T. HIRAI, A. YAMAUCHI, A. OGO, H. MATSUMOTO, T. UENO ( <i>Okayama; Hiroshima, Japan</i> ) .....	5043
Anticancer Effect of a Spiro-acridine Compound Involves Immunomodulatory and Anti-angiogenic Actions. S. SOUSA DUARTE, D.K. FRADE SILVA, T.M. HONORATO LISBOA, R. GALDINO GOUVEIA, R.C. FERREIRA, R.O. DE MOURA, J.M. DA SILVA, É. DE ALMEIDA LIMA, S. RODRIGUES-MASCARENHAS, P.M. DA SILVA, D.F. FARIAS, J.A. DA COSTA RIBEIRO SOUZA, K.C. DE PAULA MEDEIROS, J.C. RAMOS GONÇALVES, M. VIEIRA SOBRAL ( <i>João Pessoa; Recife; Natal, Brazil</i> ) .....	5049
Cetyltrimethylammonium Bromide Suppresses the Migration and Invasion of Hepatic Mahlavu Cells by Modulating Fibroblast Growth Factor Signaling. T.-K. WU, C.-H. CHEN, W.-T. LEE, T.-F. SU, Y.-R. PAN, F.-M. HUANG, C.-J. LEE ( <i>Taichung; Miaoli; Changhua, Taiwan, ROC</i> ).....	5059
Setanaxib as a Potent Hypoxia-specific Therapeutic Agent Against Liver Cancer. S. OWADA, H. ENDO, C. OKADA, K. YOSHIDA, Y. SHIDA, M. TATEMICHII ( <i>Isehara, Japan</i> ) .....	5071
Novel Imidazo[2,1-b]oxazole Derivatives Inhibit Epithelial Cell Transformation and Triple Negative Breast Cancer Tumorigenesis. P.Y. BHATTARAI, C.-H. OH, G. KIM, M.S. KIM, B.S. LEE, H.S. CHOI ( <i>Gwangju; Seoul; Hwaseong, Republic of Korea</i> ) .....	5081
YM155 Reverses Cabazitaxel Resistance in Castration-resistant Prostate Cancer by Reducing Survivin Expression. T. MIYAO, H. KOIKE, Y. SEKINE, A. OHTSU, D. OKA, K. SUZUKI ( <i>Maebashi, Japan</i> ) .....	5091
Assessing the Anti-cancer Therapeutic Mechanism of a Herbal Combination for Breast Cancer on System-level by a Network Pharmacological Approach. H.-S. LEE, D.-S. OH ( <i>Daejeon, Republic of Korea</i> ).....	5097
Anti-tumor Effect of Hedgehog Signaling Inhibitor, Vismodegib, on Castration-resistant Prostate Cancer. A. ISHII, K. SHIGEMURA, K. KITAGAWA, S.-Y. SUNG, K.-C. CHEN, C. YI-TE, M.-C. LIU, M. FUJISAWA ( <i>Kobe, Japan; Taipei, Taiwan, ROC</i> ) .....	5107
Antitumor Effect of Shikonin, a PKM2 Inhibitor, in Cholangiocarcinoma Cell Lines. U. THONSRI, W. SEUBWAI, S. WARAASAWAPATI, S. WONGKHAM, T. BOONMARS, U. CHA'ON, C. WONGKHAM ( <i>Khon Kaen, Thailand</i> ) .....	5115
Anti-progressive Effects of a Series of Glycinylnyl and Alaninylnyl Triazolyl-oxazolidinones on Kelly Neuroblastoma Cell Line. N.A. AL-HASAWI, O.A. PHILLIPS, F. AL-AWADHI, L.H. SHARAF, S.A. AMINE, L. NOVOTNY ( <i>Kuwait City, Kuwait</i> ) .....	5125



A Potential Mechanism of Anticancer Immune Response Coincident With Immune-related Adverse Events in Patients With Renal Cell Carcinoma. T. KATO, E. TOMIYAMA, Y. KOH, M. MATSUSHITA, Y. HAYASHI, K. NAKANO, Y. ISHIZUYA, C. WANG, K. HATANO, A. KAWASHIMA, T. UJIKE, K. KAWASAKI, E. MORII, K. GOTOH, H. EGUCHI, K. KIYOTANI, K. FUJITA, N. NONOMURA, M. UEMURA ( <i>Osaka; Tokyo, Japan</i> ).....	4875
Antitumor Effects and Tumor-specificity of Guaiiazulene-3-Carboxylate Derivatives Against Oral Squamous Cell Carcinoma <i>In Vitro</i> . M. TERATANI, S. NAKAMURA, H. SAKAGAMI, M. FUJISE, M. HASHIMOTO, N. OKUDAIRA, K. BANDOW, Y. IJIMA, J. NAGAI, Y. UESAWA, H. WAKABAYASHI ( <i>Saitama; Tokyo; Kawagoe, Japan</i> ) .....	4885
Effect of Phosphoribosyltransferase Down-regulation on Malignant Glioma Cell Characteristics. M. KAMADA, K. IKEDA, Y. MANOME ( <i>Tokyo, Japan</i> ).....	4895
Luteolin Induces Cytotoxicity in Mix Cellularity Classical Hodgkin's Lymphoma <i>via</i> Caspase Activated-cell Death. R. GHARBARAN, E. SHANG, O. ONWUMERE, N. CODRINGTON, E.D. SARPONG, S. REDENTI ( <i>Bronx; New York, NY, USA</i> ).....	4907
New Imidazo[2,1- <i>b</i> ][1,3,4]Thiadiazole Derivatives Inhibit FAK Phosphorylation and Potentiate the Antiproliferative Effects of Gemcitabine Through Modulation of the Human Equilibrative Nucleoside Transporter-1 in Peritoneal Mesothelioma. G.L. PETRI, C. PECORARO, O. RANDAZZO, S. ZOPPI, S.M. CASCIOFERRO, B. PARRINO, D. CARBONE, B. EL HASSOUNI, A. CAVAZZONI, N. ZAFFARONI, G. CIRRINCIONE, P. DIANA, G.J. PETERS, E. GIOVANNETTI ( <i>Amsterdam, the Netherlands; Palermo; Parma; Milan; Pisa, Italy; Gdansk, Poland</i> ) .....	4913
Phenothiazines and Selenocompounds: A Potential Novel Combination Therapy of Multidrug Resistant Cancer. M. GAJDÁCS, M. NOVÉ, Á. CSONKA, B. VARGA, C. SANMARTÍN, E. DOMÍNGUEZ-ÁLVAREZ, G. SPENGLER ( <i>Szeged, Hungary; Pamplona; Madrid, Spain</i> ) .....	4921
Discovery of a Novel Chemical Scaffold Against Mutant Isocitrate Dehydrogenase 1 (IDH1). C.H. KANG, S.U. CHOI, Y.H. SON, H.K. LEE, H.G. JEONG, C.-S. YUN, S. AHN, C.H. PARK ( <i>Daejeon, Republic of Korea</i> ) .....	4929
ALK Inhibitors Do Not Increase Sensitivity to Radiation in EML4-ALK Non-small Cell Lung Cancer. K.THRIN FLESchUTZ, L. WALTER, R. LEISTNER, L. HEINZERLING ( <i>Erlangen; Bamberg, Germany</i> ).....	4937
Effects of Sclareol Against Small Cell Lung Carcinoma and the Related Mechanism: <i>In Vitro</i> and <i>In Vivo</i> Studies. H.L. CHEN, J.Y. GONG, S.-C. LIN, S. LI, Y.-C. CHIANG, J.-H. HUNG, C.-C. YEN, C.-C. LIN ( <i>Taichung; Keelung; New Taipei City; Tainan; Changhua, Taiwan, ROC; Blacksburg, VA, USA; Huanggang, PR China</i> ) .....	4947
Inhibition of Retinoblastoma Cell Growth by CEP1347 Through Activation of the P53 Pathway. K. TOGASHI, M. OKADA, S. SUZUKI, T. SANOMACHI, S. SEINO, M. YAMAMOTO, H. YAMASHITA, C. KITANAKA ( <i>Yamagata, Japan</i> ) .....	4961
<i>Brucea javanica</i> Increases Survival and Enhances Gemcitabine Efficacy in a Patient-derived Orthotopic Xenograft (PDOX) Mouse Model of Pancreatic Cancer. H. YANG, Z. TONG, L. SHEN, Y. SUN, R.M. HOFFMAN, J. HUANG ( <i>Hefei, PR China; San Diego, CA, USA</i> ) .....	4969
<i>CDKN1A</i> Gene Expression in Two Multiple Myeloma Cell Lines With Different P53 Functionality. D. HRCKOVA DROZDKOVA, J. GURSKY, J. MINARIK, I. ÜBERALL, Z. KOLAR, K. SMESNY TRTKOVA ( <i>Olomouc, Czech Republic</i> ) .....	4979
Ephemeranthol A Suppresses Epithelial to Mesenchymal Transition and FAK-Akt Signaling in Lung Cancer Cells. N. NONPANYA, O. PRAKHONGCHEEP, K. PETSRI, C. JITJAICHAM, S. TUNGSUKRUTHAI, B. SRITULARAK, P. CHANVORACHOTE ( <i>Bangkok, Thailand</i> ) .....	4989